Properties (46)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
InterMune in 2014
Cimzia in 2008 Gazyva in 2013 Herceptin in 1998 Perjeta in 2012 Rituxan in 1997 Vabomere in 2017 ZycoV-D in 2021 Genentech_in_2009 Atezolizumab_in_2016 Avastin_in_2004 Cemiplimab_in_2018 Cotellic_in_2015 Flatiron_Health_in_2018 Ocrevus_in_2017 Spark_Therapeutics_in_2019 Tamiflu_in_2001 Tibotec_in_2011 Venclexta_in_2016 Xeloda_in_1998 Xofluza_in_2018 |
| gptkbp:CEO |
gptkb:Severin_Schwan
|
| gptkbp:clinicalTrials |
conducts numerous
|
| gptkbp:employees |
over 100,000
|
| gptkbp:founded |
1896
|
| gptkbp:founder |
gptkb:Fritz_Hoffmann-La_Roche
|
| gptkbp:headquarters |
gptkb:Basel,_Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Hoffmann-La Roche
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:market |
global
|
| gptkbp:partnerships |
various biotech companies
|
| gptkbp:patentCitation |
holds many
|
| gptkbp:philanthropy |
engaged in charitable activities
|
| gptkbp:products |
diagnostics
medicines |
| gptkbp:research |
multiple locations
|
| gptkbp:research_areas |
metabolic disorders
neurology oncology infectious diseases immunology |
| gptkbp:researchAndDevelopment |
significant investment
|
| gptkbp:revenue |
over $60 billion (2020)
|
| gptkbp:subsidiary |
gptkb:Genentech
|
| gptkbp:sustainability_initiatives |
active
|